MedTrace Logo

Genotyping Influences Outcome of Coronary Artery Stenting

NCT02707445 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2016-03-14

No results posted yet for this study

Summary

This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.

Conditions

  • Myocardial Ischemia
  • CLOPIDOGREL, POOR METABOLISM of (Disorder)

Interventions

DRUG

Clopidogrel

Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention

Sponsors & Collaborators

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Do-sun Lim, MD, PhD · Cardiovascular center, Korea University Anam Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2016-02-29
Completion
2016-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02707445 on ClinicalTrials.gov